Loading…
← CockpitCompetitor Analysis › KNSA Kiniksa Pharmaceuticals International, plc Class AOpen in the cockpit ↗

Kiniksa Pharmaceuticals International, plc Class AKNSACompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Biotech selling Arcalyst, an interleukin blocker for recurrent pericarditis, a rare heart-lining inflammation.

Momentum leader 96
Mkt cap
$7.47B
US dollars, full cap
Free float
93%
of shares outstanding
$/day
$80.4M
20-day average traded
Fwd P/E
56.6×
forward earnings
ROIC−WACC
+62.5 pp
WACC 6.6%
Hurdle
-35 pp
Req g minus delivered
Next earnings
104 days
2 Mar 2027
Close · USD$95.05
1D-0.1%
1W-0.7%
1M+14.3%
3M+21.1%
6M+75.1%
YTD+130.4%
1Y+129.6%
ATR %4.5%
Beta0.62
52w lowhigh4.3% off high

What Kiniksa Pharmaceuticals International does

Biotech selling Arcalyst, an interleukin blocker for recurrent pericarditis, a rare heart-lining inflammation.

Sells Arcalyst as a weekly injection, taken by patients for years through specialty pharmacies, so revenue grows as more people are diagnosed and stay on treatment. It licenses Arcalyst from Regeneron, which makes the drug and receives payments in return, so a share of each sale goes back to its originator.

Products and services

  • Arcalyst (recurrent pericarditis)
  • Inflammatory-disease pipeline

Customers

  • Cardiologists/rheumatologists
  • Health systems
  • Payers

Where it sits in the supply chain

  • Pharmaceuticals
  • Biotech
  • Rare inflammatory/cardiovascular…

What could go right

  • Continued Arcalyst prescription growth as diagnosis rises
  • Pipeline maturing toward additional approvals

What could go wrong

  • Heavy reliance on a single approved drug
  • Small, niche patient population limits total market size

Moat: narrow (IP / patents, regulatory licence). First and only approved therapy specifically for recurrent pericarditis, with orphan-drug protection.

Headquarters: Lexington, Massachusetts, United States · Founded: 2015 · Employees: 366

Named competitors

Kiniksa Pharmaceuticals International at a glance

Size Kiniksa Pharmaceuticals International (KNSA) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $7.47B, the 918th largest of 3,085 United States companies the cockpit tracks. Shares closed at $95.05 on 18 Nov 2026.

Performance Over six months the shares gained 75.1%, against +2.7% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.

Growth Revenue grew 58.2% over the last twelve months (peer median +11.5%); the operating margin is 13.8% (peer median 15.1%).

Valuation It trades at 56.6× forward earnings against a peer median of 16.4× (2nd most expensive of 16).

Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +45%, so the hurdle is -35 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 62.5 points above its cost of capital (6.6% WACC).

Short interest Short interest is 8.8% of the free float (30 Oct 2026).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026KNSA 177Peer median 105
Six months, rebased to 100: Kiniksa Pharmaceuticals International against the median of its 20 peers (local-currency closes).

Kiniksa Pharmaceuticals International financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$946M$678M$423M$270M$220M
Revenue growth—+60%+57%+23%—
Gross profit$513M$370M$234M$179M$169M
EBITDA$132M$78.8M-$43.9M-$23.1M$14.0M
Net income$110M$59.0M-$43.2M$14.1M$183M
Free cash flow$197M$136M$25.4M$13.2M$5.70M
Capital expenditure$1.64M$1.57M$277,000$130,000$105,000
Total debt$7.88M$9.50M$9.86M$12.3M$5.92M

Quarterly statements and history in the cockpit →

Kiniksa Pharmaceuticals International competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%-20%0%+20%GRFCORT6001964528AMRX002821CYTKIBRXALKSBANBALK-B9926GLENMARKRYTMPTGX4151000999KNSA6-month return →1-month return →
Up and to the right = strong over both horizons. Kiniksa Pharmaceuticals International is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%0×500×1,000×1,500×GRFCORT600196PTGXKNSARevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Kiniksa Pharmaceuticals International is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%GRFCORT6001964528AMRXALKSALK-BGLENMARK601607PTGX000963ALKEM000999KNSAGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Kiniksa Pharmaceuticals International is the large dot.

Kiniksa Pharmaceuticals International competitors and peer comparison

Head to head with its named competitors (KNSA vs NOVN.SW)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Kiniksa Pharmaceuticals International KNSA$7.47B+75%+58%14%56.6×10.4%
Novartis NOVN.SW$285B+11%-4%30%17.5×1.6%

How Kiniksa Pharmaceuticals International compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Kiniksa Pharmaceuticals International against its 20 peers (data as of 18 Nov 2026)
MeasureKNSAPeer medianRank in peer set
1-month return+14.3%+1.7%3rd highest of 21
6-month return+75.1%+2.7%2nd highest of 21
Distance from 52-week high-4.3%-12.9%5th highest of 21
Revenue growth (TTM)+58.2%+11.5%4th highest of 21
Operating margin13.8%15.1%11th highest of 21
Forward P/E56.6×16.4×2nd most expensive of 16
Growth the price implies (Req g, 7 yrs)10.4%7.2%7th most demanding of 15
Growth delivered (Del g)+45.5%+9.3%highest of 15
Hurdle (Req g minus delivered)-35.0 pp-1.9 ppleast demanding of 15
ROIC minus cost of capital+62.5 pp+1.7 pp2nd highest of 19
EV / EBITDA52.2×22.6×2nd most expensive of 12
Net debt / EBITDA-4.2×0.2×least indebted of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Kiniksa Pharmaceuticals International KNSAUnited States$7.47B+75%+58%14%56.6×10.4%+45.5%
Grifols GRF.MCSpain$7.48B+19%+1%16%13.1×7.1%+7.1%
Corcept Therapeutics CORTUnited States$7.42B+15%+30%12%15.3×23.9%+16.6%
Shanghai Fosun Pharmaceutical (Group) 600196.SSChina$7.57B-14%+8%6%14.8×2.9%+6.6%
ONO Pharmaceutical 4528.TJapan$7.33B-2%-2%22%15.3×-6.8%+10.8%
Amneal Pharmaceuticals AMRXUnited States$7.62B+79%+9%16%19.2×17.2%+8.7%
Asymchem Laboratories (Tianjin) 002821.SZChina$7.27B+20%+18%17%37.4×n/an/a
Cytokinetics CYTKUnited States$7.15B-35%+30%-625%n/an/an/a
ImmunityBio IBRXUnited States$7.13B-17%+121%-150%n/an/an/a
Alkermes Public ALKSUnited States$7.87B+27%+15%5%n/a32.5%+7.3%
Bachem BANB.SWSwitzerland$7.06B0%+5%19%32.4×n/an/a
ALK-abello A/S ALK-B.CODenmark$7.94B-8%+16%26%34.8×7.3%+12.6%
Akeso 9926.HKHong Kong$7.01B-48%+42%-25%n/an/an/a
Glenmark Pharmaceuticals GLENMARK.NSIndia$7.98B+10%0%17%33.1×27.3%+9.4%
Shanghai Pharmaceuticals 601607.SSChina$8.23B0%+4%3%11.2×-10.1%+8.1%
Rhythm Pharmaceuticals RYTMUnited States$8.25B+31%+61%-67%n/an/an/a
Protagonist Therapeutics PTGXUnited States$8.30B+26%+164%59%1,532.5×17.5%+10.0%
Huadong Medicine 000963.SZChina$6.69B-18%+2%9%12.5×-3.9%+5.3%
Alkem Laboratories ALKEM.NSIndia$6.69B-5%+13%17%27.3×25.0%+10.7%
Kyowa Kirin 4151.TJapan$8.43B+9%+10%24%16.4×-4.7%+9.3%
China Resources Sanjiu Medical & Pharmaceutical 000999.SZChina$6.59B+6%+4%14%13.2×-6.2%+18.4%

Questions

Who are Kiniksa Pharmaceuticals International's main competitors?
Named competitors: Novartis (Ilaris) (NOVN.SW), Sobi (private or unlisted). The cockpit's measured peer set (industry) also includes Grifols (GRF.MC), Corcept Therapeutics (CORT), Shanghai Fosun Pharmaceutical (Group) (600196.SS), ONO Pharmaceutical (4528.T), Amneal Pharmaceuticals (AMRX), Asymchem Laboratories (Tianjin) (002821.SZ).
Is Kiniksa Pharmaceuticals International expensive compared with its peers?
On forward p/e it trades at 56.6× against a peer median of 16.4×, 2nd most expensive of 16 in its peer set. For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +45%, so the hurdle is -35 pp: the price already allows for a slowdown.
How has Kiniksa Pharmaceuticals International stock performed?
Over six months to 18 Nov 2026 the shares returned +75.1% against +2.7% for the median peer; over one year +129.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.